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Abstract
Background: After cancer diagnosis, therapy for the patient is largely dependent on the tumor origin, especially when a
metastatic tumor is being treated. However, cases such as untypical metastasis, poorly differentiated tumors or even a
limited number of tumor cells may lead to challenges in identifying the origin. Moreover, approximately 3% to 5% of total
solid tumor patients will not have to have their tumor origin identified in their lifetime. The THEROS CancerTYPE IDH is
designed for identifying the tumor origin with an objective, rapid and standardized procedure.
Methodology and Principal Findings: This is a blinded retrospective study to evaluate performance of the THEROS
CancerTYPE IDH in a Chinese population. In total, 184 formalin-fixed paraffin-embedded (FFPE) samples of 23 tumor origins
were collected from the tissue bank of Fudan University Shanghai Cancer Center (FDUSCC). A standard tumor cell
enrichment process was used, and the prediction results were compared with reference diagnosis, which was confirmed by
two experienced pathologists at FDUSCC. All of the 184 samples were successfully analyzed, and no tumor specimens were
excluded because of sample quality issues. In total, 151 samples were correctly predicted. The agreement rate was 82.1%. A
Pearson Chi-square test shows that there is no difference between this study and the previous evaluation test performed by
bioTheranostics Inc. No statistically significant decrease was observed in either the metastasis group or tumors with high
grades.
Conclusions: A comparable result with previous work was obtained. Specifically, specimens with a high probability score
(.0.85) have a high chance (agreement rate=95%) of being correctly predicted. No performance difference was observed
between primary and metastatic specimens, and no difference was observed among three tumor grades. The use of laser
capture micro-dissection (LCM) makes the THEROS CancerTYPE IDH accessible to almost all of the cancer patients with
different tumor statuses.
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Introduction
Approximately 10% to 15% of cancer patients are defined as
metastatic cancer patients when they are first diagnosed [1].
Information on the tumor origin is valuable in treatment decisions.
The accurate diagnosis of the primary site allows clinicians to
determine the stage of cancer; surgery could be applied in some
cases, and further radio- and chemotherapy or site-specific therapy
could also be of benefit for the patients. A retrospective study with
879 patients showed an increase in survival time in patients for
whom the primary site was identified [2]. However, untypical
metastasis or poorly differentiated tumors can present challenges
in identifying the tumor origin.
Increased efforts have been made to trace the origin of a tumor
using different skills and technologies. In some cases, an
experienced pathologist will know the answer by examining
hematoxylin and eosin-stained (H&E) slides. Immunohistochem-
istry (IHC) is a routine test in the pathology department and will
sometimes provide helpful information at the protein level.
However, even with an expanding panel of antibodies, it is still
not possible to obtain a convincing conclusion with IHC
independently, and this diagnosis could be more difficult in
high-grade tumors. A meta-analysis of four studies showed that
IHC correctly identified the tumor origin of 66% of specimens [3].
Some DNA tests, including loss of heterozygosity (LOH) analysis,
microsatellite analysis and oncogene mutation analysis, could be
used to show the clonal origin of a malignancy. With the evolution
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cancer lesions could finally be identified after a series of time-
consuming procedures. However, approximately 3% to 5% of
total solid tumor patients will not be able to have their tumor
origin accurately diagnosed before treatment starts or even in their
lifetime [4,5].
Recently, different molecular analyses for the expression
profiling of mRNA or miRNA were developed to identify the
primary site [6,7,8,9] using microarrays or real-time PCR
technology. Several critical mRNAs or miRNAs were profiled in
the metastatic site of tumors, and the results indicated the possible
primary site. Validation results for these molecular assays were
published, and the success rates were approximately 75.6% to
89%.
The THEROS CancerTYPE IDH is a real-time PCR-based test
that can be used to identify the origin of metastatic cancer and
determine the pathological type of a solid tumor. A total of 92
genes, including 5 reference and 87 tumor-specific genes, were
detected in FFPE samples from slides.
The 1
st version of THEROS CancerTYPE IDH was designed
and tested in 2006 [6]. A total of 578 tumor samples were selected
to develop a comprehensive database. A possibility score was given
after the test as a measurement of how similar the sample tested
was to 32 tumor origins and histological subtypes in the reference
database. Validation results showed an 87% success rate in the
classification of 32 tumor types and within 119 FFPE samples.
Further validation was demonstrated in the identification of
specimens from 20 actual CUP patients at least 2 months earlier
than their latent primary recognition, and most of these specimens
were from poorly differentiated tumors. This study showed that 15
of the 20 samples were accurately classified and corresponded to
the latent primary sites later identified [10].
THEROS CancerTYPE IDH (Version 2) was subsequently
developed. The reference tumor database was expanded to 2,206
samples, and the associated algorithm was modified to enable the
prediction of 30 main tumor types and 54 histological subtypes.
More importantly, a tumor enrichment method, laser capture
micro-dissection (LCM), was used. This addition makes the
technology applicable when limited tumor cells are available. In
a separate test set of 187 FFPE tumor samples representing 28 of
the 30 main cancer types, THEROS CancerTYPE IDH (Version
2) showed an overall sensitivity of 83% [11].
In this study, we aim to evaluate the performance of the
THEROS CancerType IDH (Version 2) within Chinese popula-
tion. We conducted a blinded retrospective study in which
184 FFPE samples from FDUSCC were selected, real-time PCR
was performed in Shanghai, and the generated raw data were
analyzed by bioTheranostics in San Diego. The prediction results
were generated by bioTheranostics. The assay performance within
several subgroups, including different technologies and tumor
characteristics, was compared.
Materials and Methods
Study Design
This is a blinded retrospective study to evaluate the perfor-
mance of the THEROS CancerTYPE IDH in Chinese population.
FFPE samples of 23 tumor origins were selected from FDUSCC.
Clinical history and H&E slides were confirmed by at least 2
experienced pathologists. Tumor cells were dissected from FFPE
slides by scraping or LCM. After overnight digestion with
proteinase K, a standard protocol was applied to isolate and
reverse transcribe RNA. A 92-gene Taqman real-time PCR panel
was then used for each sample. PCR data were generated and sent
to the CLIA lab at bioTheranostics Inc. for analysis. The data
were generated using a previously described method without
knowing any of the clinical information, except for gender and
organ location in which the tissues were obtained [6,11].
A total of 184 samples of 23 tumor main types were selected for
this study, and these samples are described in Table 1. These
samples were separated into 2 groups for analysis according to the
difficulty of clinical assessment and practice: 139 samples of 17
tumor types were classified into groups in which the primary site
(n=102, 73.4%) and metastasis site (n=37, 26.6%) were
identified. The remaining 45 samples of 6 tumor types, including
sarcoma, neuroendocrine, mesothelioma, skin, melanoma and
lymphoma cancer, could arise in many parts of the body or in
multiple organs; therefore, it is not easy to accurately determine
the primary site or origin of the tumor. For example, lymphoma
could be found at both sides of the diaphragm when diagnosed,
and the exact origin could not be determined. In addition, these 6
types of tumors are not in the report of the THEROS
CancerTYPE IDH. We decided to compare these 45 samples
separately for their primary and metastatic tumors. The patient
clinical characteristics are illustrated in Table 2.
Patients and Tumor Specimens
A total of 184 tumor samples were obtained from the tissue
bank of FDUSCC. Tumor types that were not in the THEROS
CancerType IDH diagnostic list were not included, and FFPE
blocks before 2008 were also not included in this study. Diagnoses
were made based on necessary medical history review, physical
evaluation, imaging procedures and full pathologic workup,
including H&E staining. All of the cases were reviewed and
diagnosed by at least two pathologists.
For each sample, a minimum of 300 tumor cells should be
obtained after dissection. No other special inclusion criteria, such
as weight, tumor representation and minimal necrosis rate, were
required due to the dissection technology used.
FFPE Slides and Tumor Cells Enrichment
Samples were embedded in paraffin with a standard FFPE
protocol and stored in the tissue bank of FDUSCC. The H&E
slides for each tumor block were examined to confirm the
existence of tumor cells. Samples with a large tumor area and high
tumor cells content without necrosis are prepared for manual
dissection. Other samples with large interfering areas, such as
normal cells, necrotic areas, fibrocytes, and lymphocyte infiltra-
tions, or with low tumor representation and multiple discrete
tumor cells under the microscope were labeled for LCM [12].
FFPE blocks were prepared for each treatment as three unstained
10-mm glass slides (for scrape) or membrane slides (for LCM) and
one H&E-stained slide. Further treatment included deparaffiniza-
tion, circling the area of the tumor (only for scrape) or staining
(only for LCM) and proteinase K digestion overnight.
In total, the tumor cells of 127 specimens were dissected by
LCM, and the remaining 57 specimens were scraped.
RNA Extraction and Pre-amplification
After proteinase K (Life Technologies, Inc.) treatment overnight
(16–20 h), RNA extraction was performed with a Zymo RNA
Extraction Kit (ZYMO research) according to the recommended
protocol. Then, 10 ml of purified RNA was treated by DNAse (Life
Technologies, Inc.) to eliminate genome DNA contamination in
the PCR process. After reverse transcription by poly-T and
random hexamer primers, a pre-amplification step was performed
with an ABI pre-AMP kit (Life Technologies, Inc.).
92-Gene Profile in Identification of Cancer Origin
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THEROS CancerTYPE IDH (Version 2) is a Taqman-based
real-time PCR assay that detects the expression level of 92 genes
and distinguishes 30 tumor types. Within these 92 genes, 5
reference genes with stable expression across the broad spectrum
of tissues are used for scaling and QC. The remaining 87 genes
were expressed in multiple tumors. Approximately 80% of these
genes have functional annotation, including DNA-binding tran-
scription factors, cell membrane proteins and several well-
characterized tumor markers [6].
The assay was processed with prefabricated ABI 384 plates.
Four samples were applied to each 384 plate. To control the
quality of experiments, a negative control and a positive control
Table 1. No. of cases for each cancer type and primary or
metastasis site.
Cancer Type
No. of
Cases
Primary
Site Metastasis Site
Ovary 14 10 4
Mucinous adenocarcinoma 4
Clear cell adenocarcinoma 1
Endometrioid 1
Serous 8
Sarcoma 13 / /
Gastro esophageal 12 7 5
Adenocarcinoma 11
Squamous 1
Head & Neck 10 7 3
Salivary 6
squamous 4
Urinary Bladder 10 6 4
TCC 9
Adenocarcinoma 1
Germ-cell 10 10 0
Germinomatous 2
Non-Germinomatous 4
Mixed 4
Breast 10 7 3
Ductal carcinoma 6
Lobular carcinoma 2
Mucinous adenocarcinoma 2
Thyroid 10 6 4
Papillary 4
Follicular 2
Medullary 4
Neuroendocrine 9 / /
Gastrointestinal carcinoid 4
Lung carcinoid 1
Lung large cell 1
Lung small cell 2
Pancreatic islet cell carcinoid 1
Kidney 8 8 0
Chromophobe 2
Clear cell 5
Transitional cell 1
Lung 8 7 1
Large cell 4
Squamous 4
Intestine 8 2 6
Colon adenocarcinoma 8
Mesothelioma 7 / /
Pancreas 7 6 1
Adenocarcinoma 7
Prostate 7 7 0
Adenocarcinoma 7
Endometrium 6 3 3
Table 2. Patient clinical characters.
Patient Gender
Male 90
Female 94
Tumor Grade
I (Low grade) 12
II (Intermediate grade) 28
III (High grade) 50
Not specified 94
Primary and metastasis
Primary 102
Metastasis 37
Not specified 45
doi:10.1371/journal.pone.0039320.t002
Table 1. Cont.
Cancer Type
No. of
Cases
Primary
Site Metastasis Site
Adenocarcinoma 2
Adeno-squamous carcinoma 1
Clear cell carcinoma 2
Skin 6 / /
Basal cell carcinoma 3
Squamous 3
GIST 6 6 0
Liver 6 5 1
Gallbladder 5 4 1
Adenocarcinoma 5
Melanoma 5 / /
Lymphoma 5 / /
MALT 2
DLBCL 2
Burkitt 1
Adrenal 2 1 1
Pheochromocytoma 1
Cortical carcinoma 1
Total 184 102 37
doi:10.1371/journal.pone.0039320.t001
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replaces the real sample with H2O, and the positive control is a
universal human RNA purchased from Stratagene, Inc. Primer
pairs and MGB Taqman probes were designed to produce an
amplicon of less than 80 bps and synthesized by Sangon Biotech
(Shanghai). The aliquoting of pre-amplified samples was per-
formed in a 10 ml volume in a prefabricated 384 plate.
Amplifications were performed with an ABI 7900HT RT-PCR
system with the following conditions: 50uC for 2 minutes, 95uC for
10 minutes, and 45 cycles of 95uC for 15 seconds and 60uC for 1
minute. The raw data were generated with default settings.
Data Analysis
Raw data were identified with biopsy site and gender and sent
to bioTheranostics, Inc. without any other clinical information.
With the KNN (K nearest neighbor) algorithm, the expression
profiles of the samples were compared with a pre-established
database. A standard report was generated for each sample and
sent back. The report included a prediction result with a
probability score indicating the similarity of the tested samples
to the profiling data in the database. The standard reports and
clinical diagnosis were compared to calculate the agreement rate.
Statistics between several subgroups, such as high and low RNA
quality, LCM and scraping, primary site and metastasis site, well
and poor differentiation, were also described to demonstrate the
performance of the THERO CancerType IDH. The performance
of THERO CancerType IDH Version 1 and Version 2 was also
compared and described.
Results
Assay Performance
The 184 samples were composed of 23 cancer types within the
THEROS CancerTYPE IDH working list. We calculated the rate
of agreement between the reference diagnosis and THEROS
CancerTYPE IDH prediction results (Table 3). An agreement rate
of 82.1% (151/184) was achieved for all of the samples. Moreover,
the specimens from adrenal, breast, germ cell, GIST, intestinal,
liver, lymphoma, prostate and thyroid cancer were 100% correctly
classified. The specimens from neuroendocrine, kidney, lung, skin,
gallbladder, melanoma and urinary bladder cancer showed an
agreement rate higher than 80%. For each type of cancer, we
calculated the sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) with the following
formulas:
Sensitivity: the ability to predict true positives = true positives/
total observed positives.
Specificity: the ability to predict true negatives = true
negatives/total observed negatives.
PPV: fraction of true positives among the predictive positives =
true positives/total number of predicted positives.
NPV: fraction of true negatives among the predictive negatives
= true negatives/total number of predicted negatives.
Average Reference Gene Ct (ARG Ct) Value and
Probability Score
In this study, RNA was extracted from FFPE slides by either
scraping or LCM. These methods usually result in unfavorable
RNA quantity and integrity. Because of the scarcity of these
samples, we do not check the RNA quality after it was extracted.
After real-time PCR is performed, the average Ct value of 5
reference genes is used as an indication of RNA quality. Low RNA
quantity or integrity will lead to a higher Ct, indicating a non-
optimal condition of the RNA materials.
These 184 tested samples have a wide range of average
reference gene Ct values, from 21.7 to 36.3 (Figure 1). The
Kolmogorov-Smirnov test showed that these ARG Ct values were
normally distributed (P=0.2). The mean and median were 27.34
and 27.36, respectively. A total of 29 samples showed ARG Ct
values within the range of 21.7 to 25, and 26 of them were
correctly predicted (89.7%). For the range of 25 to 30, 107 of 132
(81.1%) samples were correctly predicted. For the samples having
a higher ARG Ct (.30), 18 of 23 samples (78.3%) were correctly
predicted. A Pearson Chi-square test showed no significant
difference between these 3 groups (P=0.484).
The probability score is an indicator of classification certainty.
In our test, the score ranged from 0.28 to 0.96 (Figure 2). In total,
121 of 184 samples (65.8%) showed a probability score higher than
0.85, among which only the tumor origins of 6 samples were
misclassified. The agreement rate was 95% (115/121). The
remaining 63 specimens had a probability score less than 0.85,
among which 27 samples were misclassified. The agreement rate is
much lower (57.1%, 36/63).
The probability score for all of the samples have a correlation
close to 0 (-0.003) with the ARG Ct value. A t-test showed no
difference in the ARG Ct value between the correctly classified
and misclassified group (P=0.953). However, the probability score
shows a significant difference between correct and incorrect
groups (P=1.794E-7).
Table 3. CancerType ID
H performance on 184 Chinese tumor
specimens.
Cancer Type No. of cases Sensitivity SpecificityPPV NPV
Adrenal 2 1.000 0.995 0.667 1.000
Breast 10 1.000 0.994 0.909 1.000
GIST 6 1.000 1.000 1.000 1.000
Intestine 8 1.000 0.994 0.889 1.000
Liver 6 1.000 1.000 1.000 1.000
Lymphoma 5 1.000 0.994 0.833 1.000
Prostate 7 1.000 1.000 1.000 1.000
Thyroid 10 1.000 1.000 1.000 1.000
Germ-cell 10 1.000 1.000 1.000 1.000
Neuroendocrine 9 0.889 0.983 0.727 0.994
Kidney 8 0.875 0.989 0.778 0.994
Lung 8 0.875 0.983 0.700 0.994
Skin 6 0.833 0.994 0.833 0.994
Gallbladder 5 0.800 0.983 0.571 0.994
Melanoma 5 0.800 0.994 0.800 0.994
Urinary Bladder 10 0.800 0.971 0.615 0.988
Sarcoma 13 0.769 1.000 1.000 0.983
Pancreas 7 0.714 0.994 0.833 0.989
Head & Neck 10 0.700 1.000 1.000 0.983
Ovary 14 0.643 0.976 0.692 0.971
Gastro
esophageal
12 0.583 0.988 0.778 0.971
Mesothelioma 7 0.571 1.000 1.000 0.983
Endometrium 6 0.333 0.994 0.667 0.978
doi:10.1371/journal.pone.0039320.t003
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As previously described, except for 6 tumor types (skin,
sarcoma, melanoma, mesothelioma, neuroendocrine, and lym-
phoma), 139 specimens were represented by 17 tumor types. Of
those, 102 (73.4%) were the primary tumor, and 37 were
metastases (26.6%). The classification accuracy for the primary
site and metastasis site was 86.3% (n=102) and 73.0% (n=37),
respectively.
For the metastasis group, we evaluated the biopsy site and
prediction result. Two samples shared the same tumor type label.
Both of the samples were gastro esophageal tumors metastasized to
the ovary and were predicted as ovarian cancer. Additionally,
tumor cells for both specimens were isolated by LCM. This
misclassification could possibly be caused by technical mistakes in
LCM. After removing these 2 samples, the agreement rate of the
metastasis group was 77.1%.
In clinical practice, many unknown primary cancers were first
identified in lymph nodes. In most of these cases, there were
limited tumor cells and high contamination from lymphocytes. In
our data set, 19 tumor specimens were obtained from lymph
nodes. The overall accuracy was 68.4% (n=19).
According to Fisher’s exact test, the performance for primary
site, metastasis site and lymph node metastasis samples was not
significantly different (86.3%, 73.0% and 68.4%; P=0.060).
A one-way ANOVA test on average reference gene Ct values
and probability scores showed no significant difference between
primary site, metastasis and lymph node metastasis groups (ARG
Ct P=0.726; probability score P=0.996).
Performance Comparison of LCM and Scraping
In total, 127 of 184 specimens were dissected by LCM to enrich
the tumor cells in the sections, and the remaining 57 specimens
were scraped. The agreement rate is 91.2% (52/57) for the
scraping group and 78.0% (99/127) for the LCM group, and this
decrease in the LCM group is statistically significant (P=0.03).
In addition, the ARG Ct value of the LCM group decreased
significantly by 2.48 (t-test P=3.75E-11) compared with the
scraping group (mean difference). In general, the LCM samples
have a 0.05 lower probability score than scrape samples, and this
difference is also statistically significant (t-test P=0.045).
Tumor Grade and Assay Performance
Within the 184 samples, 90 have tumor grade information
(48.9%, 90/184) in their pathological reports. In total, 12 were
well differentiated (low grade or grade I), 28 were moderately
differentiated (intermediate grade or grade II) and 50 were poorly
differentiated or undifferentiated (high grade or grade III).
Figure 1. Histogram of average reference genes and number of samples. A histogram of the number of samples versus average reference
genes Ct value shows a normal distribution. It is possibly due to the nature of sample quality (both quantity and integrity) from LCM. Also this normal
distribution supports viewpoint that ARG Ct value is a good indicator for sample quality.
doi:10.1371/journal.pone.0039320.g001
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(21/28) for grade II and 76% (38/50) for grade III (Table 4).
However, the performance differences are not statistically signif-
icant (Fisher’s exact test P=0.884). The ANOVA test also showed
that both the probability score and the ARG Ct value were not
significantly different among the three groups (P=0.298 for ARG
Ct; P=0.096 for probability score).
Performance Comparison with Previous Study
In a previous study by Ma et al., the THEROS CancerTYPE
IDH assay (Version 1) was evaluated by testing 119 FFPE tumor
samples. The overall accuracy was 82% within 32 tumor types
from 26 tumor origins.
Compared to THERO CancerType IDH (Version 1), THERO
CancerType IDH (Version 2) was developed later. The reference
tumor database was expanded to 2,206 samples, and the
associated algorithm was adjusted to enable the prediction of a
modified list of 30 main tumor types and 54 histological subtypes.
In the test set of 187 FFPE tumor samples representing 28 of the
30 main cancer types, the THERO CancerType IDH (Version 2)
showed an overall sensitivity of 83% in previous validation in an
American population [11].
In order to compare the performance of previous test set of Ma
et al., with our data generated by THEROS CancerTYPE IDH
assay (Version 2), previous tumor types of the CancerType ID
(Version 1) were adjusted to obtain a comparable tumor type list.
Figure 2. Histogram of probability score and number of samples. A histogram of the number of samples versus probability score shows a
highly biased distribution. Most of the samples tested have a probability score higher than 0.85 and got a very high agreement rate (95%).
doi:10.1371/journal.pone.0039320.g002
Table 4. Performance of Grade III tumors.
No. of cases
Correct
predicted Agreement rate
Germ-cell 1 1 1.00
Liver 1 1 1.00
Melanoma 1 1 1.00
Thyroid 1 1 1.00
Intestine 2 2 1.00
Breast 4 4 1.00
Ovary 7 6 0.86
Lung 6 5 0.83
Neuroendocrine 5 4 0.80
Urinary Bladder 5 4 0.80
Pancreas 3 2 0.67
Sarcoma 3 2 0.67
Gallbladder 2 1 0.50
Gastro esophageal 2 1 0.50
Head & Neck 4 2 0.50
Endometrium 3 1 0.33
doi:10.1371/journal.pone.0039320.t004
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carcinoma, lung squamous, lung large-cell and adenocarcinoma,
were combined together. While some other tumor types that had
not been tested, such as brain tumor and meningioma, were
removed. Finally, we obtained a list of 18 common main tumor
types tested for both studies. Also the assay performance has been
compared as illustrated in Table 5.
In order to compare the overall performance of THERO
CancerType IDH (Version 2) performed in American population
with our study in Chinese population, 5 main tumor types that
were not tested in this study were removed to obtain a comparable
23 tumor types in 171 samples.
The overall agreement rate is 84.8% (89/105) for the first test
set of THERO CancerType IDH (Version 1) and 84.6% (121/143)
in our study. A Pearson Chi-square test shows no significant
difference (P=0.975). (Table 5).
The comparison between the test set of 187 samples and this
study showed an agreement rate of 83.6% (143/171) versus 82.1%
(151/184). No significant difference was found (P=0.697).
(Table 6).
Discussion
To determine the origin of a tumor, clinicians should review the
medical history, perform careful physical examination, perform
different types of endoscopies and use several imaging devices,
such as mammography, tomography, MRI or PET. IHC is also a
current standard of care in tumor diagnosis. However, even with a
growing panel of antibodies, the success rate of tumor origin
determination is not completely satisfactory. A meta-analysis
showed that an extensive IHC workup correctly identified the
primary site for 66% of all metastatic specimens [3]. Gene
expression profiling has been used for tumor classification in many
studies [6–9,13]. However, in clinical practice, doctors will
encounter all types of tumor samples, from lymph node metastasis
to primary cancer, from fine needle biopsy to surgery resection,
from well-differentiated to poorly differentiated tumors and with a
variety of RNA quantity and integrity. A molecular profiling assay
that can be applied to all types of samples is required. Moreover,
due to the complexity and quantitative nature of such technology,
a standard sample inclusion step and sample treatment process
should be applied to obtain a comparable and reproducible
performance result.
In this study, we have evaluated the performance of the
THEROS CancerTYPE IDH, a real-time PCR-based 92-gene
mRNA expression profiling panel, with 184 FFPE tissue speci-
mens from Chinese patients. This study is performed blindly and
independently in an outside lab, bioTheranostics Inc., using stored
specimens in the tissue bank of FDUSCC. This study demon-
strated that the CTID assay could be carefully performed outside
of the CLIA lab in the United States with different samples taken
from Chinese population and show comparable performance. In
addition, we also tried to explore the effect of several sample
subgroups.
Published gene expression-based CUP assays often have some
sample inclusion criteria on tumor representation, minimum
necrosis and total RNA quality. For example, in the work of
Rosenfeld et al., most samples included (.90%) had at least 50%
tumor in the section area, and 5 mg of total RNA was needed [9].
In the work of Monzon et al., a visual examination by pathologists
was required, and at least 60% tumor representation and ,20%
necrosis were included [7,8]. In the previous evaluation study of
the THEROS CancerTYPE IDH by Ma et al., the average tumor
content of all samples was approximately 65% [6].
With the application of LCM, THEROS CancerTYPE IDH
(Version 2) is able to treat specimens with disseminated tumor
Table 5. A comparison on 18 common tumor types between Ma’s work with the data in this study.
CancerType ID (Version 1) FDUSCC-IM Lab (Version 2)
nr of sample tested correctly predicted nr of sample tested correctly predicted
Adrenal 11 2 2
Breast 11 1 0 1 0
Endometrium 32 6 2
Germ-cell 97 1 0 1 0
GIST 33 6 6
Intestine 87 8 8
Kidney 44 8 7
Liver 22 6 6
Lung 11 5 8 7
Lymphoma 10 10 5 5
Mesothelioma 54 7 4
Ovary 55 1 4 9
Pancreas 33 7 5
Prostate 77 7 7
Sarcoma 13 10 13 10
Skin 11 9 6 5
Thyroid 33 1 0 1 0
Urinary Bladder 66 1 0 8
Total 105 89 143 121
doi:10.1371/journal.pone.0039320.t005
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performance decrease is observed in the LCM group, it still
showed a 78% agreement rate.
However, there are technical difficulties when using LCM. Due
to the highly scattered tumor cells and low tumor representation in
some specimens, the low quantity of RNA, contamination with
surrounding cells, such as fibrocytes, lymphocytes or necrotic
areas, and RNA degradation during staining and dissection, qRT-
PCR results can be changed.
In our data, the low integrity and quantity of RNA did not
significantly affect the classification results. We observed a
decrease in the sensitivity with an increase in ARG Ct value,
but this difference was not statistically significant. In addition, no
differences in ARG Ct were found between the correctly classified
and misclassified group.
Contamination was also found in at least 2 samples. Both of
these samples are gastro esophageal tumor metastases to the ovary.
The specimens were taken from the metastatic site, and both were
predicted as ovarian cancer. Considering these technical difficul-
ties, a decrease in the classification performance from 91% in
scraped samples to 78% in LCM specimens seems unavoidable.
In clinical practice, metastases often increase the demand for
the primary tumor origin to be identified quickly and accurately.
However, many previous studies had already described the change
in morphology, IHC and mRNA profile. This change will result in
a decrease in classification accuracy by pathologists or molecular
tests based on gene expression profiles. In our data, primary
tumors showed the highest sensitivity, with an agreement rate of
86.3%. All of the 37 metastatic tumors showed a 73% agreement
rate. For some patients, the only metastasis site identified is the
lymph node. We also calculated the agreement rate of the 19
lymph node metastasis specimens and obtained 68.4% sensitivity.
However, this decrease is not significant (P=0.06).
The metastasis group had more LCM specimens. It is hard to
determine whether the performance decrease is mainly caused by
metastasis-related expression profile changes or contamination
during LCM. In addition, the limited sample size within the
metastasis group made the result less convincing.
Tumor grade may also change the morphology and expression
profile. Poorly differentiated tumors are sometimes difficult to
identify and will cause misdiagnosis. However, in our data, the 50
grade III tumor samples had a 76% agreement rate, and the
performance differences between the three grades were not
statistically significant (P=0.884).
Previously, two validations had been performed by using
samples for which the tumor origin was already identified in
American population. Our study showed the overall performance
of THEROS CancerTYPE IDH (Version 2) in Chinese population
are comparable to the previous test by THEROS CancerTYPE
IDH (Version 1) [6] and the resent test by THEROS CancerTYPE
IDH (Version 2) in American population [11]. However, the
performance for some types of cancer, such as endometrial and
Table 6. A comparison on 23 tumor types between the test set of American population with the data in this study.
CTID Version 2 (American population) CTID Version 2 (Chinese population)
nr of sample tested correctly predicted nr of sample tested correctly predicted
Adrenal 2222
Breast 11 11 10 10
Endometrium 4362
Gallbladder 6454
Gastro esophageal 14 12 12 7
Germ-cell 661 0 1 0
GIST 1166
Head & Neck 13 7 10 7
Intestine 16 10 8 8
Kidney 5587
Liver 7766
Lung 13 12 8 7
Lymphoma 10 10 5 5
Melanoma 5454
Mesothelioma 2274
Neuroendocrine 7798
Ovary 651 4 9
Pancreas 8575
Prostate 8777
Sarcoma 661 3 1 0
Skin 9665
Thyroid 551 0 1 0
Urinary Bladder 761 0 8
Total 171 143 184 151
Both study used the CancerType ID version 2.
doi:10.1371/journal.pone.0039320.t006
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such as lung cancer and intestine cancer showed an increase in
performance in these validation tests. However, due to the limited
samples of each tumor type and histology type, it is difficult to
confirm whether this performance difference was caused by an
expression profile difference between different populations or the
histology type tested.
Although a total of 184 samples were included in the study, for
certain types of tumor with small samples, the analysis have been
unable to achieve sufficient statistical power. Such as the adrenal
cancer, only 2 samples were tested. Additional study with enlarged
sample size for certain types of tumor in deed necessary in the
future.
Conclusion
We evaluated the performance of the THEROS CancerTYPE
IDH in 184 Chinese tumor specimens of 23 types. The assay was
performed blindly and independently. A low sample inclusion
criterion was set (at least 300 tumor cells), and no sample was
excluded during the inclusion and experimental stage.
A comparable result with previous work was generated, with a
total performance of 82.1%. Specifically, the specimens with a
high probability score (.0.85) had a high chance (agreement rate
=95%) of being correctly predicted. Moreover, no statistically
significant performance difference was observed between primary
and metastatic specimens, and no difference was observed among
three tumor grades. The use of LCM makes the THEROS
CancerTYPE IDH accessible to almost all of the cancer patients
with different statuses of tumor specimens. These characteristics
make the THEROS CancerTYPE IDH a valuable tool in clinical
practice.
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